MapLight goes public via $250M IPO to fund Cobenfy competitor
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The…
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The…